Portfolio company
Theratome Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops stem-cell secretome therapeutics to treat ischemic brain injury, dry eye disease and organ transplant preservation for healthcare providers and patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
HemostOD
The company develops stem cell-derived platelets for transfusion and targeted drug delivery, serving healthcare providers and pharmaceutical partners treating blood disorders or trauma.
Healome Therapeutics
The company develops eye-drop matrix technology to improve drug delivery and treatment for patients with ocular surface diseases.
StemSight
This company develops stem cell therapies using biomaterials to treat corneal blindness in patients with limbal stem cell deficiency and other eye conditions.
X-Therma
This company develops non-toxic biopreservation solutions and transport devices for healthcare and research institutions to store and transport cells, tissues and organs.
Exostemtech
This biotechnology firm develops exosome-based therapeutics and production platforms for clinical researchers and healthcare providers treating intractable diseases.
BE Therapeutics
This company develops engineered brain and spinal cord tissues to repair central nervous system damage for patients with neurodegeneration, stroke or trauma.
Clade Therapeutics
This biotechnology company develops stem cell-derived medicines to treat patients with cancer and autoimmune diseases.
Cirrus Therapeutics
This company develops gene and cell therapies to treat age-related macular degeneration and chronic vision loss for patients with blinding eye diseases.
